MetaCap

Immutep (IMMP) vs TransCode Therapeutics (RNAZ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immutep (IMMP) has outperformed TransCode Therapeutics (RNAZ) over the past year, gaining 80.8% versus a loss of 86.6%. Over five years, IMMP leads with a -8.5% price change compared with -100.0% for RNAZ. Immutep is the larger company by market cap ($22.9 million vs $20.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMMP+80.81%RNAZ-86.57%
+375%+133%-109%
Nov 21, 20251 yearNov 20, 2026
IMMP-18.37%RNAZ-100.00%
+115%+2%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMMP versus RNAZ key metrics
MetricIMMPRNAZ
Share price$3.11$1.16
Market cap$22.92M$20.07M
1-day change-9.06%-10.77%
YTD return+8.74%-83.02%
1-year return+80.81%-86.57%
5-year return-8.53%-100.00%
EPS (TTM)$-7.30$-47.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-34.66M
52-week high$70.60$12.60
52-week low$2.66$1.01
Distance from 52-week high-95.59%-90.79%
Analyst consensusnone—
Avg. price target upside+864.63%—
Average volume26.07K52.03K
Shares outstanding7.37M17.30M
Employees—12
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMMP has outperformed RNAZ by 167.4 percentage points over the past year.

About Immutep

IMMP stock →

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations

About TransCode Therapeutics

RNAZ stock →

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

IMMP vs RNAZ FAQ

Which is bigger, Immutep or TransCode Therapeutics?

Immutep (IMMP) is larger, with a market capitalization of $22.92M compared with $20.07M for TransCode Therapeutics (RNAZ).

Which stock has performed better over the past year, IMMP or RNAZ?

IMMP returned +80.81% over the past 12 months, compared with -86.57% for RNAZ (price return, excluding dividends). Past performance does not predict future results.

Are Immutep and TransCode Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons